A-Share Announcements | Algorithmic Leader Zhongke and Haiguang Information Report Performance
Today's Focus
1, Chu Ship Technology: GIGAPHOTON's certified supplier
Chu Ship Technology (688146.SH) announced that the company's light-curable gas products (Kr/Ne, Ar/Ne/Xe) have passed Japan's GIGAPHOTON's certification as a qualified supplier, with a valid certificate period until July 23, 2030. This certification demonstrates that the company's products meet international high-end semiconductor manufacturing standards for purity and stability, which will help enhance the company's market competitiveness in the electronic specialty gases sector. However, this certification itself does not constitute a direct guarantee of orders or income, and its impact on future performance is uncertain.
2, Tian'an Biological: Subsidiary company Chengdu Rongsheng Pharmaceutical Co., Ltd. reports clinical trial results
Tian'an Biological (600161.SH) announced that the company's subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd., has completed a clinical trial for the product "Injection-grade recombinant human factor IX" and obtained a summary report of the clinical trial. The product has been shown to have good safety in patients with hemophilia A, significantly reducing bleeding frequency, and improving joint health scores (HJHS scores), target joint scores, and quality-of-life scores (CHO-KLAT scores).
3, Yi Bao Pharmaceutical: Guangxi Provincial Administration of Pharmacy issues notice to temporarily suspend the production and sale of children's cough syrup
Yi Bao Pharmaceutical (600594.SH) announced that the company has received a temporary suspension notice from the Guangxi Provincial Administration of Pharmacy. During an inspection by the National Medical Products Administration, it was found that the company had deficiencies in its record-keeping and electronic data management. After comprehensive evaluation, the conclusion was that the company did not meet the requirements. According to regulations, the company is required to immediately suspend the production and sale of children's cough syrup starting from the date of receipt of this notice. The suspension of children's cough syrup production and sales will have a limited impact on the company's performance.
4, Mu Xi Shares: Sales of goods pigs reached 116.39 billion yuan in July
Mu Xi Shares (002714.SZ) announced that the company sold 635,500 heads of pigs in July, a year-on-year change of 13.02% (of which 237,700 heads were sold to its wholly-owned subsidiary, Mu Xi Meat Food Co., Ltd.). The average price per unit was 14.30 yuan/kg, down 21.86% year-on-year; and the sales revenue reached 116.39 billion yuan, a year-on-year decrease of 10.41%
5, Anche Detection: Controlling shareholder changes to Silicon Valley Technology; shares resume trading
Anche Detection (300572.SZ) announced that Silicon Valley Technology is expected to acquire the company's controlling shareholder, He Xianning, who holds 6.43% of the company's shares, in a private transaction. The parties agree that after the transfer of the first phase of shares, He Xianning will delegate his voting rights to Silicon Valley Technology (referred to as "this equity change"). Before the completion of this equity change, He Xianning plans to transfer his 13.57% stake in the company to Silicon Valley Technology. After the completion of this equity change, the company's controlling shareholder will be changed from He Xianning to Silicon Valley Technology, and the actual controller will be changed from He Xianning to none. The company's shares are expected to resume trading on August 6, 2025.
Performance
1, Haiguang Information: Net profit of RMB 12.01 billion in the first half year
Haiguang Information released its semi-annual report for 2025, with a net profit of RMB 12.01 billion, up 40.78% year-on-year; basic earnings per share of RMB 0.52.
2, Zhongke Dawn: Net profit of RMB 7.31 billion in the first half year
Zhongke Dawn released its semi-annual report for 2025, with a net profit of RMB 7.31 billion, up 29.89% year-on-year; basic earnings per share of RMB 0.5.
Share Repurchase and Capital Increase
1, Chenxin Pharmaceutical: Shareholder plans to reduce holdings by up to 3% of the company's shares
Chenxin Pharmaceutical announced that a shareholder holding over 5% of the company's shares, Han Yanzheng, plans to reduce his holdings by up to 453 million shares, representing no more than 1% of the company's total shares; and by up to 906 million shares through block transactions, representing no more than 2%, totaling not exceeding 1358 million shares, representing no more than 3%. The reduction plan is based on the shareholder's own financial needs and will not significantly affect the company's governance structure or long-term operations.
2, Chanlian Shares: Jiayu Investment plans to reduce holdings by up to 2.96% of the company's shares
Chanlian Shares announced that a shareholder holding 2.96%, Jiayu Investment Co., Ltd., plans to reduce its holdings by up to 1072.09 million shares through concentrated bidding and block transactions, representing no more than 2.96%
3, Oride: Shared by Shunbo Creative Investment
Oride announced that the company's controlling shareholder, actual controller, and chairman, Zhang Lisheng, plans to reduce his holdings by up to 8290.5 million shares through concentrated bidding and block transactions, representing no more than 3% of the company's total shares.
4, Xinpeng Micro: Controlling shareholder and chairman plans to reduce holdings by up to 2% of the company's shares
Xinpeng Micro announced that the company's controlling shareholder, actual controller, and chairman, Zhang Lisheng, plans to reduce his holdings by up to 262.62 million shares through concentrated bidding and block transactions, representing no more than 2%
5, Guangge Technology: Shareholder plans to reduce holdings by up to 4.04% of the company's shares
Guangge Technology announced that a shareholder, Kaisi Ventures, plans to reduce its holdings by up to 266.64 million shares through concentrated bidding and block transactions, representing no more than 4.04%